- Other markets
- IG services
- Trading platforms
- IG analysis
No data available for this market
BRIEF: For the fiscal year ended 31 December 2014, Enzon Pharmaceuticals Inc revenues decreased 10% to $31.2M. Net income increased 59% to $28.8M. Revenues reflect Miscellaneous income decrease of 79% to $135K. Net income reflects General and administrative decrease of 73% to $2.4M (expense), Restructuring charges decrease from $4.8M (expense) to $0K, Research and development decrease from $2.7M (expense) to $0K.
* If your stockbroking account is accessible under the same login as your spread betting or CFD account, you can automatically qualify for our lowest commission rate by placing at least one spread bet or CFD trade in the previous calendar month. See our full charges and fees.